Literature DB >> 24296585

Emerging strategies to deplete the HIV reservoir.

Nancie M Archin1, David M Margolis.   

Abstract

PURPOSE OF REVIEW: This review highlights recent studies undertaken to further advance the search for successful approaches to eradicate HIV infection. RECENT
FINDINGS: Small pharmacological compounds such as histone deacetylase inhibitors, inhibitors of bromodomain and extraterminal proteins such as JQ1, and protein kinase C activators such as bryostatin and prostratin are proposed as putative candidates for inducing the expression of latent HIV in a so-called 'shock and kill' or 'kick and kill' strategy for HIV eradication. However, in order to achieve viral clearance, it is thought likely these compounds will have to be administered in concert with strategies that augment clearance of virus-infected cells in patients that have long been aviremic on successful antiretroviral therapy (ART). Several candidate therapies for this purpose are at hand, such as therapeutic HIV vaccines - recently shown to promote robust cytotoxic T cell responses and blunt viral rebound after ART interruption in clinical studies. HIV-infected patients treated during early infection may be ideal candidates for early studies to test these strategies, as early ART has been shown to limit the establishment of an HIV reservoir.
SUMMARY: HIV latency is multifactorial and thus the eradication of HIV infection may require multiple approaches. Translational efforts employing pharmacological methods to target HIV latency should evaluate in parallel the additional potential benefits of invigorating the immune response of HIV-infected individuals, and limiting the size of the reservoir via early ART.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24296585      PMCID: PMC4031321          DOI: 10.1097/QCO.0000000000000026

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  42 in total

1.  Prostratin antagonizes HIV latency by activating NF-kappaB.

Authors:  Samuel A Williams; Lin-Feng Chen; Hakju Kwon; David Fenard; Dwayne Bisgrove; Eric Verdin; Warner C Greene
Journal:  J Biol Chem       Date:  2004-07-28       Impact factor: 5.157

2.  A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1.

Authors:  K R Gustafson; J H Cardellina; J B McMahon; R J Gulakowski; J Ishitoya; Z Szallasi; N E Lewin; P M Blumberg; O S Weislow; J A Beutler
Journal:  J Med Chem       Date:  1992-05-29       Impact factor: 7.446

3.  The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices.

Authors:  D E Schaufelberger; M P Koleck; J A Beutler; A M Vatakis; A B Alvarado; P Andrews; L V Marzo; G M Muschik; J Roach; J T Ross
Journal:  J Nat Prod       Date:  1991 Sep-Oct       Impact factor: 4.050

4.  Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals.

Authors:  G Sanchez; X Xu; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  IkappaBepsilon-deficient mice: reduction of one T cell precursor subspecies and enhanced Ig isotype switching and cytokine synthesis.

Authors:  S Mémet; D Laouini; J C Epinat; S T Whiteside; B Goudeau; D Philpott; S Kayal; P J Sansonetti; P Berche; J Kanellopoulos; A Israël
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

7.  Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors:  Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal:  N Engl J Med       Date:  2013-10-23       Impact factor: 91.245

8.  Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.

Authors:  Joaquín Rullas; Mercedes Bermejo; Javier García-Pérez; Manuela Beltán; Nuria González; Marjan Hezareh; Stephen J Brown; José Alcamí
Journal:  Antivir Ther       Date:  2004-08

9.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

10.  In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

Authors:  T W Chun; D Finzi; J Margolick; K Chadwick; D Schwartz; R F Siliciano
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  96 in total

1.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.

Authors:  Victoria E K Walker-Sperling; Valerie J Cohen; Patrick M Tarwater; Joel N Blankson
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

3.  Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

Authors:  Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  MicroRNA-155 Reinforces HIV Latency.

Authors:  Debbie S Ruelas; Jonathan K Chan; Eugene Oh; Amy J Heidersbach; Andrew M Hebbeler; Leonard Chavez; Eric Verdin; Michael Rape; Warner C Greene
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

Review 5.  Potential implication of residual viremia in patients on effective antiretroviral therapy.

Authors:  Gautam K Sahu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

6.  Studies on the regio- and diastereo-selective epoxidation of daphnanes and tiglianes.

Authors:  Pierre-Luc Boudreault; Jennifer K Mattler; Paul A Wender
Journal:  Tetrahedron Lett       Date:  2015-06       Impact factor: 2.415

7.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 8.  HIV-1 target cells in the CNS.

Authors:  Sarah B Joseph; Kathryn T Arrildt; Christa B Sturdevant; Ronald Swanstrom
Journal:  J Neurovirol       Date:  2014-09-19       Impact factor: 2.643

9.  Sensitivity of the C-Terminal Nuclease Domain of Kaposi's Sarcoma-Associated Herpesvirus ORF29 to Two Classes of Active-Site Ligands.

Authors:  Jennifer T Miller; Haiyan Zhao; Takashi Masaoka; Brittany Varnado; Elena M Cornejo Castro; Vickie A Marshall; Kaivon Kouhestani; Anna Y Lynn; Keith E Aron; Anqi Xia; John A Beutler; Danielle R Hirsch; Liang Tang; Denise Whitby; Ryan P Murelli; Stuart F J Le Grice
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

10.  Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

Authors:  Brian Reardon; Nadejda Beliakova-Bethell; Celsa A Spina; Akul Singhania; David M Margolis; Douglas R Richman; Christopher H Woelk
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.